Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Aimmune Therapeutics

This publication has 27 references indexed in Scilit: